When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?

AIDS

Volumn 26, Issue 9, 2012, Pages 1095-1103

  Read, Phillip J ^a   Mandalia, Sundhiya ^b   Khan, Palwasha ^c   Harrisson, Ursula ^b   Naftalin, Claire ^d   Gilleece, Yvonne ^d   Anderson, Jane ^c   Hawkins, David A ^b   Taylor, Graham P ^e   De Ruiter, Annemiek ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d UK   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

HAART; HIV; mother to child transmission; pregnancy; treatment; viral load

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM; VAGINAL DELIVERY; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELIVERY, OBSTETRIC; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84862789323     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283536a6c     Document Type: Article

References (20)

1. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. The European Collaborative Study. AIDS 1999; 13:1377-1385.
2. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341:394-402.
3. Contopoulos-Ioannidis DG, Ioannidis JP. Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:126-135.
4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
5. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353:1035-1039.
6. Boer K, England K, Godfried MH, Thorne C. Mode of delivery in HIV-infected pregnant women and prevention of mother-tochild transmission: changing practices in Western Europe. HIV Med 2010; 11:368-378.
7. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-465.
8. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981.
9. Hawkins D, Blott M, Clayden P, et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Med 2005; 6 (Suppl 2):107-148.
10. Lyall E, Blott M, de Ruiter A, et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. HIV Med 2001; 2:314-334.
11. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States; 14 September 2011. pp. 1-207. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. [Accessed 12 February 2012]
12. BuchholzB,BeichertM,MarcusU,etal.German-Austrianrecommendations for HIV1-therapyin pregnancyandinHIV1-exposed newborn, update 2008. Eur J Med Res 2009; 14:461-479.
13. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9:452-502.
14. Clinical Management and Treatment of HIV-infected adults in Europe verions 5.4. European AIDS Clinical Society; 2011. http://www. europeanaidsclnicalsociety.org/images/stories/EACS-pdf/1 treatment of HIV infected adults.pdf. [Accessed 15 July 2011]
15. Antiretroviral drugs for treating pregnant women and preventing HIV infection in Infants. World Health Organisation; 2010. http://whqlibdoc.who.int/ publications/2010/9789241599818-eng.pdf. [Accessed 15 July 2011]
16. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2011. Wilmington, NC: Registry Coordinating Center; 2011. www.APRegistry.com. [Accessed 1 November 2011]
17. Tubiana R, Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load
18. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
19. Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44:1647-1656.
20. Katz IT, Shapiro R, Li D, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr 2010; 54:27-34.